Study of fecal calprotectin detection in patients with inflammatory bowel disease in Jiading district of Shanghai of China

doi:10.3877/cma.j.issn.2095-2015.2021.05.001

Abstract

Abstract:

Objective

To investigate the value of fecal calprotectin(FC)in the diagnosis of patients with inflammatory bowel disease(IBD)in Jiading district of Shanghai of China.

Methods

The fecal samples of 43 subjects from March 2020 to May 2020 in North District of Shanghai Ruijin Hospital were collected and divided into two groups: IBD group(n=28)and healthy control group(n=15). Fluorescence immunochromatography was used to quantitatively detect FC concentration in feces.

Results

The FC concentration in 15 healthy subjects was 40.63 μg/g, and that in 28 patients with was 323.45 μg/g.There was a significant difference in FC concentration between IBD group and control group(P<0.05). When 60 μg/g was taken as the critical value, the sensitivity and specificity of FC to determine whether IBD was active or not were 82.14% and 86.67%, respectively.There were also significant differences in FC concentrations between active IBD patients and inactive IBD patients and healthy subjects(P<0.05).

Conclusion

FC test, as a non-invasive diagnosis and treatment method, can be used as an alternative index for endoscopic diagnosis of disease activity, which has a good application value in the diagnosis of IBD and the assessment of disease activity in Jiading district of Shanghai of China.

Key words: Fecal calprotectin, Inflammatory bowel disease, Disease activity index, Ulcerative colitis, Crohn′s disease

Cuiping Yang, Xu Quan, Shunchang Sun, Mengyin Zhang, Jinye Zhang, Ying Jia, Xiaojun Yu, Ling Xie, Bo′er Cai, Yunlin Wu, Ping Chen. Study of fecal calprotectin detection in patients with inflammatory bowel disease in Jiading district of Shanghai of China[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2021, 11(05): 193-195.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2021.05.001

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2021/V11/I05/193

Figures/Tables 2

References 24

1	中华医学会消化病学分会炎症性肠病协作组．中国炎症性肠病诊断治疗规范的共识意见[J]．中华内科杂志，2008，47(1):73-79.
2	Flynn S, Eisenstein S．Inflammatory Bowel Disease Presentation and Diagnosis[J]．Surg Clin North Am，2019，99(6):1051-1062.
3	Echarri Piudo A．Inflammatory bowel disease - Newer models of care[J]．Rev Esp Enferm Dig，2019，111(8):577-578.
4	Hanić M, Trbojević-AkmaičIć, Lauc G．Inflammatory bowel disease-glycomics perspective[J]．Biochim Biophys Acta Gen Subj，2019，1863(10):1595-1601.
5	Pisani LF, Moriggi M, Gelfi C，et al.Proteomic insights on the metabolism in inflammatory bowel disease[J]．World J Gastroenterol，2020，26(7):696-705.
6	Johne B, Fagerhol M K, Lybrg T，et al.Functional and cEnical aspects of the myelomonocyte protein calprotectin[J]．J Clin Path-Mol Path，1997，50(3):113-123.
7	Gebhardt C, Nemeth J, Angel P，et al.S100A8 and S100A9 in inflammation and cancer[J]．Biochemical Pharmacology，2006，72(11):1622-1631.
8	Roseth AG, Schmidt PN, Fagerhol MK.Correlation between faecal excretion of indium-111 -labelled granulocytes and calprotectin，a granulocyte maricer protein，in patients with inflammatory bowel disease[J]．Scand J Gagtroentero，1999，34(1):50-54.
9	Sander J, Fagerlol MK, Bakkon JS，et al.Plasma levels of the leukocyte LI protein in febrile conditions：relation to aetilolgy t number of leucocytes in blood，blood sedimentation reaction and C-reaction protein[J]．Scand J Clin Lav Invest，1984，44(4):357-362.
10	Ayling RM, Kok K．Fecal Calprotectin[J]．Adv Clin Chem，2018，87:161-190.
11	Ricciuto A, Griffiths AM.Clinical value of fecal calprotectin[J]．Crit Rev Clin Lab Sci，2019，56(5):307-320.
12	Vernia F, Di Ruscio M, Stefanelli G，et al.Is fecal calprotectin an accurate marker in the management of Crohn′s disease？[J]．J Gastroenterol Hepatol，2020，35(3):390-400.
13	20 Caviglia GP, Ribaldone DG, Rosso C，et al.Fecal calprotectin：beyond intestinal organic diseases[J]．Panminerva Med，2018，60(1):29-34.
14	Mumolo MG, Bertani L, Ceccarelli L，et al.From bench to bedside：Fecal calprotectin in inflammatory bowel diseases clinical setting[J]．World J Gastroenterol，2018，24(33):3681-3694.
15	Mosli MH, Zou G, Garg SK，et al.C-Reactive Protein，Fecal Calprotectin，and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients：A Systematic Review and Meta-Analysis[J]．Am J Gastroenterol，2015，110(6):802-819;quiz 820.
16	Sharbatdaran M, Holaku A, Kashifard M，et al.Fecal calprotectin Level in patients with IBD and noninflammatory disease of colon：a study in Babol，Northern，Iran[J]．Caspian J Intern Med，2018，9(1):60-64.
17	Sands BE.Biomarkers of Inflammation in Inflammatory Bowel Disease[J]．Gastroenterology，2015，149(5):1275-1285.
18	Roseth A G, Fageriiol M K, Aadland E．Assessment of the neutrophil dominating protein calprotectin in feces，a methodogic study[J]．Scand J Gastroenterol，1992，27(9):793-798.
19	Inch R D, Pont E D, Leo V D，et al.Calprotectin and lactoferrin in the assessmen of intestinal inflammation and organic disease[J]．Int J Colorectal Dis，2007，22(4)429-437.
20	Schoepfer A M, Trummler M, Seeholzer P，et al.Accuracy of four fecal assays in the diagnosis of colitis[J]．Dis Colon Rectum，2007，50(10):1697-1706.
21	Younes C．Fecal calprotectin and RT-PCR from both nasopharyngeal swab and stool samples prior to treatment decision in IBD patients during CoVID-19 outbreak[J]．Dig Liver Dis，2020，52(11):1230.
22	Menees SB, Powell C, Kurlander J，et al.A meta-analysis of the utility of C-reactive protein，erythrocyte sedimentation rate，fecal calprotectin，and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS[J]．Am J Gastroenterol，2015，110(3):444-454.
23	Klingberg E, Magnusson MK, Strid H，et al.A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin[J]．Arthritis Res Ther，2019，21(1):248.
24	Bertani L, Mumolo MG, Tapete G，et al.Fecal calprotectin：current and future perspectives for inflammatory bowel disease treatment[J]．Eur J Gastroenterol Hepatol，2020，32(9):1091-1098.

组别	例数	±s	M	Q_L～Q_U	min～max
健康者	15	42.95±12.78	28.62	15.43～176.74	9.53～176.74
炎症性肠病^a	28	323.45±24.69	224.69	65.12～977.59	12.4～977.59

组别	例数	±s	M	Q_L～Q_U	min～max
健康者	15	42.95±12.78	28.62	15.43～176.74	9.53～176.74
炎症性肠病^a	28	323.45±24.69	224.69	65.12～977.59	12.4～977.59

组别		例数	±s	M	Q_L～Q_U	min～max
健康者^a		15	42.95±12.78	28.62	15.43～176.74	9.53～176.74
炎症性肠病
	活动期^b	20	425.44±88.26	388.26	218.42～977.57	12.4～977.57
	静止期	8	62.25±17.48	57.48	38.16～121.13	12.4～121.63

组别		例数	±s	M	Q_L～Q_U	min～max
健康者^a		15	42.95±12.78	28.62	15.43～176.74	9.53～176.74
炎症性肠病
	活动期^b	20	425.44±88.26	388.26	218.42～977.57	12.4～977.57
	静止期	8	62.25±17.48	57.48	38.16～121.13	12.4～121.63

[1]	Jianming Zhang, Wenhui Ye, Tingyu Mou, Xiaoliang Lan, Haijun Deng. To analyze the recent complications of laparoscopic proctocolectomy ileal j-pouch anal anastomosis and their prevetion and treatment strategies [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 388-395.
[2]	Yuqing Qiao, Lei Shen, Linxiang Zhou, Xiangjie Li, Bo Yan. The effect of connective tissue growth factor monoclonal antibody on intestinal fibrosis in mice with chronic colitis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(02): 125-131.
[3]	Xiu Wang, Yiguo Wang. Efficacy and safety of ustekinumab in treating perianal fistulizing Crohn′s disease: a meta-analysis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 514-519.
[4]	Xiao Qu, Liang Wang, Ping Lu, Bin He, Min Sun. Correlation analysis of inflammatory factors in peripheral blood and characteristics of Gut microbiota with the condition of patients with active Ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 466-470.
[5]	Fengshang Zhu, Ling She, Yongnian Ding, Changqing Yang. Maintaining vigilance in the differential diagnosis of inflammatory bowel disease and rare bowel disorders [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 273-276.
[6]	Xiaodong Yu, Dehua Li, Shan Gao, Xin Xu. Clinical observation on the treatment of mild active Crohn′s disease by combining Jiawei Lizhong Decoction with mesalazine [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 199-202.
[7]	Tingting Chen, Xueliang Jiang, Jiali Yu, Jianlin Ke. Safety of stem cells in the treatment of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 193-198.
[8]	Jiali Yu, Xueliang Jiang. Application progress of biological agents from the perspective of therapeutic strategy transformation of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(03): 129-134.
[9]	Xiang Liao, Shuang Li, Yao Zeng. Analysis of research trends and hotspots of fecal microbiota transplantation from 2012 to 2021 [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 93-99.
[10]	Wensong Ge. Dual targeted therapy for the management of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 65-67.
[11]	Sucong Lyv, Guoqiang Zhong, Jin Li, Mingsong Li. Psychological problems associated with inflammatory bowel disease and its progress in diagnosis and treatment [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(01): 33-38.
[12]	Keyi Wei, Changqing Xu, Jing Yang. Application of nanomedicines in targeted therapy of biologics for inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(06): 367-372.
[13]	Xueliang Jiang, Jianlin Ke, Tingting Chen, Jiali Yu. Effects of different doses of bifidobacterium tetralogy viable tablets on intestinal flora imbalance in patients with mild and moderate active ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(05): 260-264.
[14]	Meng Wang, Dongyan Xu, Xiaoyu Zhang, Haijian Zhao. Analysis of anal function and quality of life in patients with inflammatory bowel disease associated with perianal diseases [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(04): 224-227.
[15]	Quanlong Yang, Chongxi Fan, Xuehui Shi, Mengnan Xu, Tao Sun, Shoubin Ning. Advances in the pathogenesis and relationship between intestinal flora and inflammatory bowel disease [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2022, 09(03): 148-151.

Please choose a citation manager

Content to export